Ocrelizumab subanalysis hints at better efficacy with active inflammatory lesions

NEW ORLEANS – The greatest effect of the investigational, B-cell–targeting humanized monoclonal antibody ocrelizumab in treating primary progressive multiple sclerosis (PPMS) may be in patients with...
Source: Clinical Neurology News - Category: Neurology Source Type: news